« Previous Next »Clinical Gastroenterology and Hepatology
Volume 5, Issue 8 , Pages 890-897, August 2007

Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B

Emmet B. Keeffe
- Stanford University School of Medicine, Stanford, California
- E.B.K. is a consultant to and member of the speakers’ bureau for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Novartis, and Roche, and receives grant support from Roche and Romark.
- Address requests for reprints to: Emmet B. Keeffe, MD, Stanford University School of Medicine, 750 Welch Road, Suite 210, Palo Alto, California 94304-1509. fax: (650) 498-5692.
Stefan Zeuzem
- J.W. Goethe University Hospital, Frankfurt, Germany
- S.Z. is a consultant, member of the speakers’ bureau, and/or a clinical investigator for Gilead, GlaxoSmithKline, Idenix, Novartis, Roche, and Schering-Plough.
Raymond S. Koff
- University of Connecticut School of Medicine, Farmington, Connecticut
- R.S.K. is a consultant to Idenix and Roche and a member of the speakers’ bureau for Roche and Bristol-Myers Squibb.
Douglas T. Dieterich
- Mount Sinai School of Medicine, New York, New York
- D.T.D. is a consultant, member of the speakers’ bureau, and receives grant support from Bristol-Myers Squibb, Idenix, Gilead, and Roche.
Rafael Esteban–Mur
- Universitat Autonoma de Barcelona, Barcelona, Spain
- R.E.-M. is a consultant and member of the speakers’ bureau for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Novartis, Schering-Plough, and Vertex.
Edward J. Gane
- Auckland Hospital, Auckland, New Zealand
- E.J.G. is a consultant on advisory boards for GlaxoSmithKline, Idenix, and Novartis, and has served as a speaker for GlaxoSmithKline and Novartis.
Ira M. Jacobson
- Weill Medical College of Cornell University, New York, New York
- I.M.J. is a consultant for Bristol-Myers Squibb, Coley, Gilead, GlaxoSmithKline, GlobImmune, Human Genome Sciences, Idenix, Intermune, Merck, Novartis, Nucleonics, Phizer, Schering, Valeant, and Vertex, and a member of the speakers’ bureau for Bristol-Myers Squibb, Gilead, Schering, and TAP, and receives grant support from Coley, Gilead, GlobImmune, Idenix, Intermune, Schering, Valeant, and Vertex.
Seng G. Lim
- National University Hospital, Singapore
- S.G.L. is a consultant to Bristol-Myers Squibb, GlaxoSmithKline, Idenix, Novartis, and Schering-Plough, a member of the speakers’ bureau for Gilead and GlaxoSmithKline, and receives grant support from Novartis.
Nikolai Naoumov
- University College London Institute of Hepatology, London, United Kingdom
- N.N. is currently an employee of Novartix Pharma, which began in March 2007 after completion of the work on this manuscript; he was formerly a consultant to, member of the speakers’ bureau, and/or a clinical investigator for Gilead GlaxoSmithKline, Idenix, Novartis, Roche, and Schering.
Patrick Marcellin
- Hôpital Beaujon, Clichy, France
- P.M. is a consultant for Bristol-Myers Squibb, Coley, Cytheris, Gilead, GlaxoSmithKline, Human Genome Sciences, Idenix, Intermune, Novartis, Roche, Schering-Plough, Valeant, Vertex, and Wyeth, and receives grant support from Bristol-Myers Squibb, Cytheris, Gilead, GlaxoSmithKline, Human Genome Sciences, Idenix, Intermune, Novartis, Roche, Schering-Plough, Valeant, Vertex, and Wyeth, and is a speaker for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Novartis, Roche, Schering-Plough, and Schering-Plough.
Teerha Piratvisuth
- Songklanagarind Hospital, Hat Yai, Thailand
- T.P. is a consultant to GlaxoSmithKline, Novartis, Roche, and Schering-Plough, and has received grant support from Bristol-Myers Squibb, Novartis, and Roche.
Fabien Zoulim
- INSERM, Université Lyon and Hospices Civils de Lyon, Hôtel Dieu, Liver Department, Lyon, France
- F.Z. is a consultant for Abbott, Gilead, Idenix, and Novartis, a member of the speakers’ bureau for Bristol-Myers Squibb, Gilead, Idenix, and Novartis, and receives research support from Biomerieux, Bioalliance, and Gilead.